P62 anti-cancer DNA Vaccine (CureLab Oncology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameP62 anti-cancer DNA Vaccine (CureLab Oncology)
Drug Alias NameElenagen
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsSequestosome 1 inhibitors
TargetsSequestosome 1
Therapy Area/IndicationsOvarian NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelarus
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCurelab Oncology
China Registration ClassN/A

Develop Information

Active CompaniesCurelab Oncology
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A